These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
180 related articles for article (PubMed ID: 22560567)
1. Discovery of XL413, a potent and selective CDC7 inhibitor. Koltun ES; Tsuhako AL; Brown DS; Aay N; Arcalas A; Chan V; Du H; Engst S; Ferguson K; Franzini M; Galan A; Holst CR; Huang P; Kane B; Kim MH; Li J; Markby D; Mohan M; Noson K; Plonowski A; Richards SJ; Robertson S; Shaw K; Stott G; Stout TJ; Young J; Yu P; Zaharia CA; Zhang W; Zhou P; Nuss JM; Xu W; Kearney PC Bioorg Med Chem Lett; 2012 Jun; 22(11):3727-31. PubMed ID: 22560567 [TBL] [Abstract][Full Text] [Related]
2. Aminopyrimidinone cdc7 kinase inhibitors. Woods KW; Lai C; Miyashiro JM; Tong Y; Florjancic AS; Han EK; Soni N; Shi Y; Lasko L; Leverson JD; Johnson EF; Shoemaker AR; Penning TD Bioorg Med Chem Lett; 2012 Mar; 22(5):1940-3. PubMed ID: 22326396 [TBL] [Abstract][Full Text] [Related]
3. 2-Aminomethylthieno[3,2-d]pyrimidin-4(3H)-ones bearing 3-methylpyrazole hinge binding moiety: Highly potent, selective, and time-dependent inhibitors of Cdc7 kinase. Kurasawa O; Homma M; Oguro Y; Miyazaki T; Mori K; Uchiyama N; Iwai K; Ohashi A; Hara H; Yoshida S; Cho N Bioorg Med Chem; 2017 Jul; 25(14):3658-3670. PubMed ID: 28533114 [TBL] [Abstract][Full Text] [Related]
4. First Cdc7 kinase inhibitors: pyrrolopyridinones as potent and orally active antitumor agents. 2. Lead discovery. Menichincheri M; Bargiotti A; Berthelsen J; Bertrand JA; Bossi R; Ciavolella A; Cirla A; Cristiani C; Croci V; D'Alessio R; Fasolini M; Fiorentini F; Forte B; Isacchi A; Martina K; Molinari A; Montagnoli A; Orsini P; Orzi F; Pesenti E; Pezzetta D; Pillan A; Poggesi I; Roletto F; Scolaro A; Tatò M; Tibolla M; Valsasina B; Varasi M; Volpi D; Santocanale C; Vanotti E J Med Chem; 2009 Jan; 52(2):293-307. PubMed ID: 19115845 [TBL] [Abstract][Full Text] [Related]
5. A Cdc7 kinase inhibitor restricts initiation of DNA replication and has antitumor activity. Montagnoli A; Valsasina B; Croci V; Menichincheri M; Rainoldi S; Marchesi V; Tibolla M; Tenca P; Brotherton D; Albanese C; Patton V; Alzani R; Ciavolella A; Sola F; Molinari A; Volpi D; Avanzi N; Fiorentini F; Cattoni M; Healy S; Ballinari D; Pesenti E; Isacchi A; Moll J; Bensimon A; Vanotti E; Santocanale C Nat Chem Biol; 2008 Jun; 4(6):357-65. PubMed ID: 18469809 [TBL] [Abstract][Full Text] [Related]
6. Synthesis and structure-activity relationship of trisubstituted thiazoles as Cdc7 kinase inhibitors. Reichelt A; Bailis JM; Bartberger MD; Yao G; Shu H; Kaller MR; Allen JG; Weidner MF; Keegan KS; Dao JH Eur J Med Chem; 2014 Jun; 80():364-82. PubMed ID: 24793884 [TBL] [Abstract][Full Text] [Related]
7. The potent Cdc7-Dbf4 (DDK) kinase inhibitor XL413 has limited activity in many cancer cell lines and discovery of potential new DDK inhibitor scaffolds. Sasi NK; Tiwari K; Soon FF; Bonte D; Wang T; Melcher K; Xu HE; Weinreich M PLoS One; 2014; 9(11):e113300. PubMed ID: 25412417 [TBL] [Abstract][Full Text] [Related]
8. N-substituted azaindoles as potent inhibitors of Cdc7 kinase. Bryan MC; Falsey JR; Frohn M; Reichelt A; Yao G; Bartberger MD; Bailis JM; Zalameda L; Miguel TS; Doherty EM; Allen JG Bioorg Med Chem Lett; 2013 Apr; 23(7):2056-60. PubMed ID: 23481650 [TBL] [Abstract][Full Text] [Related]
9. Cdc7 as a potential new target for cancer therapy. Ito S; Taniyami C; Arai N; Masai H Drug News Perspect; 2008 Nov; 21(9):481-8. PubMed ID: 19180266 [TBL] [Abstract][Full Text] [Related]
10. Synthesis and evaluation of pyrido-thieno-pyrimidines as potent and selective Cdc7 kinase inhibitors. Zhao C; Tovar C; Yin X; Xu Q; Todorov IT; Vassilev LT; Chen L Bioorg Med Chem Lett; 2009 Jan; 19(2):319-23. PubMed ID: 19071019 [TBL] [Abstract][Full Text] [Related]
11. The optimization of aminooxadiazoles as orally active inhibitors of Cdc7. Harrington PE; Bourbeau MP; Fotsch C; Frohn M; Pickrell AJ; Reichelt A; Sham K; Siegmund AC; Bailis JM; Bush T; Escobar S; Hickman D; Heller S; Hsieh F; Orf JN; Rong M; San Miguel T; Tan H; Zalameda L; Allen JG Bioorg Med Chem Lett; 2013 Dec; 23(23):6396-400. PubMed ID: 24120542 [TBL] [Abstract][Full Text] [Related]
12. Cdc7 kinase inhibitors: pyrrolopyridinones as potential antitumor agents. 1. Synthesis and structure-activity relationships. Vanotti E; Amici R; Bargiotti A; Berthelsen J; Bosotti R; Ciavolella A; Cirla A; Cristiani C; D'Alessio R; Forte B; Isacchi A; Martina K; Menichincheri M; Molinari A; Montagnoli A; Orsini P; Pillan A; Roletto F; Scolaro A; Tibolla M; Valsasina B; Varasi M; Volpi D; Santocanale C J Med Chem; 2008 Feb; 51(3):487-501. PubMed ID: 18201066 [TBL] [Abstract][Full Text] [Related]
13. Discovery of a Novel, Highly Potent, and Selective Thieno[3,2- Kurasawa O; Miyazaki T; Homma M; Oguro Y; Imada T; Uchiyama N; Iwai K; Yamamoto Y; Ohori M; Hara H; Sugimoto H; Iwata K; Skene R; Hoffman I; Ohashi A; Nomura T; Cho N J Med Chem; 2020 Feb; 63(3):1084-1104. PubMed ID: 31895562 [TBL] [Abstract][Full Text] [Related]
14. Cdc7 kinase inhibitors: 5-heteroaryl-3-carboxamido-2-aryl pyrroles as potential antitumor agents. 1. Lead finding. Menichincheri M; Albanese C; Alli C; Ballinari D; Bargiotti A; Caldarelli M; Ciavolella A; Cirla A; Colombo M; Colotta F; Croci V; D'Alessio R; D'Anello M; Ermoli A; Fiorentini F; Forte B; Galvani A; Giordano P; Isacchi A; Martina K; Molinari A; Moll JK; Montagnoli A; Orsini P; Orzi F; Pesenti E; Pillan A; Roletto F; Scolaro A; Tatò M; Tibolla M; Valsasina B; Varasi M; Vianello P; Volpi D; Santocanale C; Vanotti E J Med Chem; 2010 Oct; 53(20):7296-315. PubMed ID: 20873740 [TBL] [Abstract][Full Text] [Related]
15. Targeting cell division cycle 7 kinase: a new approach for cancer therapy. Montagnoli A; Moll J; Colotta F Clin Cancer Res; 2010 Sep; 16(18):4503-8. PubMed ID: 20647475 [TBL] [Abstract][Full Text] [Related]
17. Identification of a new class of potent Cdc7 inhibitors designed by putative pharmacophore model: Synthesis and biological evaluation of 2,3-dihydrothieno[3,2-d]pyrimidin-4(1H)-ones. Kurasawa O; Oguro Y; Miyazaki T; Homma M; Mori K; Iwai K; Hara H; Skene R; Hoffman I; Ohashi A; Yoshida S; Ishikawa T; Cho N Bioorg Med Chem; 2017 Apr; 25(7):2133-2147. PubMed ID: 28284870 [TBL] [Abstract][Full Text] [Related]
18. Discovery of novel furanone derivatives as potent Cdc7 kinase inhibitors. Irie T; Asami T; Sawa A; Uno Y; Hanada M; Taniyama C; Funakoshi Y; Masai H; Sawa M Eur J Med Chem; 2017 Apr; 130():406-418. PubMed ID: 28279847 [TBL] [Abstract][Full Text] [Related]
19. Imidazopyridine derivatives as potent and selective Polo-like kinase (PLK) inhibitors. Sato Y; Onozaki Y; Sugimoto T; Kurihara H; Kamijo K; Kadowaki C; Tsujino T; Watanabe A; Otsuki S; Mitsuya M; Iida M; Haze K; Machida T; Nakatsuru Y; Komatani H; Kotani H; Iwasawa Y Bioorg Med Chem Lett; 2009 Aug; 19(16):4673-8. PubMed ID: 19589677 [TBL] [Abstract][Full Text] [Related]